Key Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Yangjiang, China.
Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Front Cell Infect Microbiol. 2024 Mar 27;14:1356353. doi: 10.3389/fcimb.2024.1356353. eCollection 2024.
Carbapenem-resistant (CRAB) is resistant to almost all antibiotics. Eravacycline, a newer treatment option, has the potential to treat CRAB infections, however, the mechanism by which CRAB isolates develop resistance to eravacycline has yet to be clarified. This study sought to investigate the features and mechanisms of eravacycline heteroresistance among CRAB clinical isolates. A total of 287 isolates were collected in China from 2020 to 2022. The minimum inhibitory concentration (MIC) of eravacycline and other clinically available agents against were determined using broth microdilution. The frequency of eravacycline heteroresistance was determined by population analysis profiling (PAP). Mutations and expression levels of resistance genes in heteroresistant isolates were determined by polymerase chain reaction (PCR) and quantitative real-time PCR (qRT-PCR), respectively. Antisense RNA silencing was used to validate the function of eravacycline heteroresistant candidate genes. Twenty-five eravacycline heteroresistant isolates (17.36%) were detected among 144 CRAB isolates with eravacycline MIC values ≤4 mg/L while no eravacycline heteroresistant strains were detected in carbapenem-susceptible (CSAB) isolates. All eravacycline heteroresistant strains contained OXA-23 carbapenemase and the predominant multilocus sequence typing (MLST) was ST208 (72%). Cross-resistance was observed between eravacycline, tigecycline, and levofloxacin in the resistant subpopulations. The addition of efflux pump inhibitors significantly reduced the eravacycline MIC in resistant subpopulations and weakened the formation of eravacycline heteroresistance in CRAB isolates. The expression levels of and were significantly higher in resistant subpopulations than in eravacycline heteroresistant parental strains ( < 0.05). An IS insertion in the gene was identified in 40% (10/25) of the resistant subpopulations. Decreasing the expression of or by antisense RNA silencing significantly inhibited eravacycline heteroresistance. In conclusion, this study identified the emergence of eravacycline heteroresistance in CRAB isolates in China, which is associated with high expression of AdeABC and AdeRS.
耐碳青霉烯类抗生素(CRAB)几乎对所有抗生素都具有耐药性。依拉环素是一种新的治疗选择,具有治疗 CRAB 感染的潜力,然而,CRAB 分离株对依拉环素产生耐药性的机制尚未阐明。本研究旨在探讨 CRAB 临床分离株中依拉环素异质性耐药的特征和机制。2020 年至 2022 年期间,在中国共收集了 287 株分离株。采用肉汤微量稀释法测定了依拉环素和其他临床可用药物对 的最小抑菌浓度(MIC)。通过群体分析谱(PAP)确定了依拉环素异质性耐药的频率。通过聚合酶链反应(PCR)和实时定量 PCR(qRT-PCR)分别确定异质性耐药分离株中耐药基因的突变和表达水平。使用反义 RNA 沉默来验证依拉环素异质性耐药候选基因的功能。在 144 株依拉环素 MIC 值≤4mg/L 的 CRAB 分离株中检测到 25 株依拉环素异质性耐药分离株(17.36%),而在碳青霉烯敏感 (CSAB)分离株中未检测到依拉环素异质性耐药菌株。所有依拉环素异质性耐药株均含有 OXA-23 碳青霉烯酶,主要的多位点序列分型(MLST)为 ST208(72%)。在耐药亚群中观察到依拉环素、替加环素和左氧氟沙星之间的交叉耐药性。在耐药亚群中加入外排泵抑制剂可显著降低依拉环素 MIC,并减弱 CRAB 分离株中依拉环素异质性耐药的形成。与依拉环素异质性耐药亲本株相比,耐药亚群中 和 的表达水平显著升高( < 0.05)。在 40%(10/25)的耐药亚群中发现了 基因中的 IS 插入。通过反义 RNA 沉默降低 或 的表达可显著抑制依拉环素异质性耐药。综上所述,本研究在中国发现了 CRAB 分离株中依拉环素异质性耐药的出现,这与 AdeABC 和 AdeRS 的高表达有关。